secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001558370-25-011949
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio starts Phase 2 XTX301 (IL-12), gets $17.5M milestone from Gilead; cash extended to Q1 2027
--------------------------------------------------------------------------------

- Initiated patient dosing in Phase 2 of efarindodekin alfa (XTX301) for advanced solid tumors; RP2D selected.
- Achieved $17.5M development milestone under Gilead license agreement; expects payment in Q4 2025.
- As of June 30, 2025, cash and equivalents $121.6M; plus milestone extends cash runway into Q1 2027.
- Phase 1 data: two partial responses (1 confirmed, 1 unconfirmed) in late-line advanced solid tumors; generally well-tolerated.
- Gilead can elect to transition development after specified clinical data package for a $75M fee; Xilio eligible for up to $500M in milestones plus royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025011949/0001558370-25-011949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837025011949/xlo-20250909x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-011949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer